Pegfilgrastim
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00019 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 26 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | severe nonproliferative diabetic retinopathy | KG + DL |
| 2 | diabetic retinopathy | KG + DL |
| 3 | primary release disorder of platelets | KG + DL |
| 4 | diabetic cataract | KG + DL |
| 5 | pseudo-von Willebrand disease | KG + DL |
| 6 | Glanzmann thrombasthenia | KG + DL |
| 7 | drug-induced osteoporosis | KG + DL |
| 8 | senile cataract | KG + DL |
| 9 | cortical cataract | KG + DL |
| 10 | nuclear senile cataract | KG + DL |
| 11 | immature cataract | KG + DL |
| 12 | craniostenosis cataract | KG + DL |
| 13 | diabetes mellitus type 2 associated cataract | KG + DL |
| 14 | mature cataract | KG + DL |
| 15 | tetanic cataract | KG + DL |
| 16 | dermatitis | KG + DL |
| 17 | hemorrhagic disease of newborn | KG + DL |
| 18 | acrodermatitis chronica atrophicans | KG + DL |
| 19 | neonatal dermatomyositis | KG + DL |
| 20 | pityriasis simplex | KG + DL |
| 21 | thrombocytopenia due to immune destruction | KG + DL |
| 22 | hydroa vacciniforme, familial | KG + DL |
| 23 | acne keloid | KG + DL |
| 24 | amyopathic dermatomyositis | KG + DL |
| 25 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
| 26 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.